Investing Ideas
/
Egyptian Pharmaceuticals & Biotech Undervalued based on future growth

Egyptian Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E	ج.م3.34	-1.5%	95.9%	ج.م5.0b	ج.م5.02	PE18.9x	E30.7%	2.0%

Page 1 of 1